Systemic Sclerosis: An Update PDF Print E-mail
Friday, 08 March 2013 00:33
Systemic sclerosis (SSc) is a clinically heterogeneous, systemic disorder affecting connective tissue of skin, internal organs, and walls of blood vessels. It is characterized by alterations of the microvasculature in the form of hypoxia, digital ulcers, and pulmonary arterial hypertension; disturbances of the immune system, including dysbalance of cytokine expression, autoantibodies (Auto-ab), and abnormalities of blood progenitor and/or effector cells; and by massive deposition of collagen in the connective tissue of the skin and various internal organs.

This review discusses epidemiology and survival; clinical features including subsets and internal organ involvement; pathophysiology including genetics, microvasculature, immunobiology, fibroblasts (FBs), and connective tissue metabolism; and environmental factors. Early diagnosis and individually tailored therapy help to manage this disorder. Therapy involves immunomodulation and targeting of blood vessels and fibrosis. The multicenter online database “European Scleroderma Trials and Research” project allows further insight of prognostic factors and conception of new therapies. Physical and psychotherapy are important.

To read the full review, click on and download from the link provided below.

 
More articles :

» Low-Dose Naltrexone for Pruritus in Systemic Sclerosis

Tracy Frech, Kirsten Novak, Monica P. Revelo, Maureen Murtaugh, Boaz Markewitz, Nathan Hatton, Mary Beth Scholand, Edward Frech, David Markewitz, and Allen D. SawitzkeReceived 31 May 2011; Accepted 14 July 2011Systemic sclerosis (SSc; scleroderma)...

» Central Nervous System Manifestations In Scleroderma

We at the believe that knowledge is indeed, power. It was this belief that became the primary motivation for the creation of our website. It was meant to empower all patients to take control of the disease through news and informative articles, and...

» New Classification Criteria Developed For Scleroderma

The 2013 Classification Criteria for Systemic Sclerosis have been developed and validated by the and and should allow patients to be identified and treated earlier, according to the professional bodies.Published in Arthritis and Rheumatism, the...

» Pulmonary Hypertension In Systemic Sclerosis

A.J. MacGregor, R. Canavan, C. Knight, C.P. Denton, J. Davar, J. Coghlan, and C.M. BlackPublished: 2001

» Interleukin-6: A New Therapeutic Target in Scleroderma

Interleukin-6 (IL-6) is a classic pro-inflammatory cytokine critical in mounting an effective immune response. It is secreted by a wide array of cell types; however, its effector cells are more restricted, owing to the fact that very few cells,...

» Joint Involvement And Aggressive Systemic Sclerosis

Clinical joint involvement is strikingly common in patients with systemic sclerosis () and is associated with a more active and severe disease phenotype, according to an analysis of the world’s largest systemic sclerosis (SSc) registry. proved to...